Skip to main content
Clinical Trials/EUCTR2009-011445-13-BE
EUCTR2009-011445-13-BE
Active, not recruiting
Phase 1

Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer

Institut Jules Bordet-Université Libre de Bruxelles0 sites225 target enrollmentSeptember 10, 2009

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Stage III colon adenocarcinoma
Sponsor
Institut Jules Bordet-Université Libre de Bruxelles
Enrollment
225
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 10, 2009
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Institut Jules Bordet-Université Libre de Bruxelles

Eligibility Criteria

Inclusion Criteria

  • \* Age 18 years or older
  • \* Clinical/radiological evaluation compatible with stage III colon adenocarcinoma
  • \*No prior chemotherapy
  • \* No prior abdominal or pelvic irradiation
  • \*WHO performance status 0 or 1
  • \*Effective contraception during the study and the following six months
  • \*Signed informed consent obtained prior to any study\-specific screening procedures
  • \*Tumour considered as curatively resectable (R0\) based on standard preoperative evaluations
  • \*White blood cell count \= 3×109/L with neutrophils \= 1\.5×109/L, platelet count \= 100×109/L, haemoglobin \= 9 g/dL (5\.6 mmol/L)
  • \*Direct bilirubin \= 1\.5×ULN; ASAT and ALAT \= 2\.5×ULN; Alkaline phosphatase \= 2\.5×ULN; Serum creatinine \= 1\.5×ULN

Exclusion Criteria

  • \*Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to screening. Incompletely healed wounds or anticipation of the need for major surgical procedure during the course of the study
  • \*Any suspicion of metastatic disease
  • \*Rectal cancer located within 15 cm from the anal verge by endoscopy or under the peritoneal reflection at surgery
  • \*Inflammatory bowel disease
  • \*Pregnancy (absence to be confirmed by ß\-hCG blood test) or breast\-feeding
  • \*History or current central nervous system disease or peripheral neuropathy
  • \*Hypersensitivity to any of the components of study treatments
  • \* Previous malignancy in the last five years except basal\-cell carcinoma of the skin or in situ cervical carcinoma
  • \*Clinically relevant coronary artery disease or history of myocardial infarction in the last 6 weeks or high risk of uncontrolled arrhythmia
  • \*Medical, geographical, sociological, psychological or legal conditions that would not permit the patient to complete the study or sign informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials